Angiotensin News and Research RSS Feed - Angiotensin News and Research

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.
Study calls for new protocols to treat women with high blood pressure

Study calls for new protocols to treat women with high blood pressure

That blood pressure plays a role in human health has been known for quite a while. Hypertension - the medical term for high blood pressure - was first described as a disease in the early 1800s, and the inflatable cuff that's used in measuring blood pressure was invented in 1896. [More]
President of Institute of Medicine to deliver presentation at University of Louisville

President of Institute of Medicine to deliver presentation at University of Louisville

The president of the Institute of Medicine of the National Academies will present the 2014 Leonard Leight Lecture at the University of Louisville. [More]
Pivotal Therapeutics announces accomplishments, financial results for Q3 2014

Pivotal Therapeutics announces accomplishments, financial results for Q3 2014

Pivotal Therapeutics Inc., ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its accomplishments and financial results for the three months ended September 30, 2014. [More]
Investigational drug maintains normal potassium levels in patients with chronic kidney disease

Investigational drug maintains normal potassium levels in patients with chronic kidney disease

Research published today found that the investigational drug patiromer decreased high potassium levels and maintained normal potassium levels in patients with chronic kidney disease. The results of a multicenter trial appear in the New England Journal of Medicine. [More]
Investigational treatment shows promise against Marfan syndrome

Investigational treatment shows promise against Marfan syndrome

An investigational treatment for Marfan syndrome is as effective as the standard therapy at slowing enlargement of the aorta, the large artery of the heart that delivers blood to the body, new research shows. The findings indicate a second treatment option for Marfan patients, who are at high risk of sudden death from tears in the aorta. [More]
New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that positive new preclinical data was presented on RG-012 for the treatment of renal dysfunction in Alport syndrome patients at the American Society of Nephrology's Kidney Week 2014 meeting being held November 11-16, 2014 in Philadelphia, PA. [More]
Study suggests that beta blockers may benefit patients suffering from HFPEF

Study suggests that beta blockers may benefit patients suffering from HFPEF

A novel registry study from Karolinska Institutet in Sweden suggests that beta blockers may benefit also patients suffering from a relatively unknown form of heart failure called HFPEF, which today lacks well-established treatment. [More]
Vascular receptor autoantibodies implicated in SSc-PAH

Vascular receptor autoantibodies implicated in SSc-PAH

medwireNews: Autoantibodies to endothelin receptor type A and angiotensin receptor type-1 predict the development of, and mortality from, systemic sclerosis-associated pulmonary arterial hypertension, research suggests. [More]
Reducing heart failure deaths: an interview with Dimitrios Georgiopoulos, UK Medical Director, Novartis

Reducing heart failure deaths: an interview with Dimitrios Georgiopoulos, UK Medical Director, Novartis

Heart failure is a debilitating, and life-threatening, condition in which the heart cannot pump enough blood around the body. When heart failure continues to progress and worsen over time, the persistent condition is known as chronic heart failure. [More]
Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen (NASDAQ: AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas. [More]
Expert creates new evidence-based guideline for managing sickle cell disease

Expert creates new evidence-based guideline for managing sickle cell disease

An expert panel has created a new evidence-based guideline for managing sickle cell disease (SCD), with a strong recommendation for the use of the drug hydroxyurea and transfusion therapy for many individuals with SCD, although high-quality evidence is limited, with few randomized clinical trials conducted for this disease, according to an article in the September 10 issue of JAMA. [More]
FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Silvergate Pharmaceuticals, Inc., focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Epaned for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure). [More]
Novel polypill increases patient adherence to treatment following heart attack

Novel polypill increases patient adherence to treatment following heart attack

New research shows a novel polypill increases patient adherence to treatment following a myocardial infarction (MI) or heart attack, according to new study results reported at the European Society of Cardiology's ESC Congress 2014 in Barcelona, Spain. [More]
Investigational LCZ696 drug: A real breakthrough for patients with heart failure

Investigational LCZ696 drug: A real breakthrough for patients with heart failure

An investigational new heart failure drug could be poised to change the face of cardiology based on Hot Line results presented today at ESC Congress 2014. [More]
Heart failure is major public health burden in many LMICs

Heart failure is major public health burden in many LMICs

Heart failure is a major public health burden in many low- and middle-income countries (LMICs), with substantial variation in the presentation, causes, management, and outcomes of heart failure across different LMICs, according to a study published in this week's PLOS Medicine. [More]
Inadequate management common in young-onset Type 2 diabetes

Inadequate management common in young-onset Type 2 diabetes

Patients with young-onset Type 2 diabetes have worse metabolic control than those with late-onset disease, but they are less likely to receive organ-protective drugs, show data from the Joint Asia Diabetes Evaluation cohort. [More]
Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate Nefecon® issued in the key markets United States, Europe, China and Hong Kong. A patent is pending in Japan. [More]
U.S. scientists fail to study possible role of innate variation in athletic performance

U.S. scientists fail to study possible role of innate variation in athletic performance

Compared to scientists working in other countries, U.S.-based scientists are underrepresented as authors of articles on the potential role of innate variation in athletic performance that are published in peer-reviewed science journals, according to Grand Valley State University researchers. [More]
Researchers discover analgesic mechanism that prevents pain in Buruli ulcer patients

Researchers discover analgesic mechanism that prevents pain in Buruli ulcer patients

When the body receives an injury to the skin, a signal is sent to the brain, which generates a sensation of pain. [More]
FDA accepts Symplmed's Prestalia NDA for hypertension treatment

FDA accepts Symplmed's Prestalia NDA for hypertension treatment

Symplmed announced today that the U.S. Food and Drug Administration has accepted for review its New Drug Application (NDA) for investigational drug Prestalia, the first single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate for the treatment of hypertension in the U.S. Symplmed filed the application under section 505(b)(2) consistent with FDA's guidance. [More]